Prodia Passes the 2019 Westgard Sigma Verification Program

Jakarta, 13 March 2019 - PT Prodia Widyahusada Tbk (ticker symbol: PRDA) has once again gotten another branch certified through the Westgard Sigma Verification Program (WSVP) organized by Westgard QC Inc., USA. The certificate ceremony was attended by Dewi Muliaty, Prodia’s Managing Director; Andri Hidayat, Prodia’s Operations and IT Director; Sten Westgard, Director of Client Services and Technology for Westgard QC Inc.; and Douglas WH Chung, APAC’s Marketing Manager of Abbott Diagnostics. Currently, six Prodia branches, namely Prodia National Referral Laboratory (PRN), Prodia Bekasi, Prodia Bandung, Prodia Malang, Prodia Semarang, and Prodia Surabaya have passed the verification. Prodia is the first and the only Indonesian clinical laboratory qualifying for WSVP.

WSVP is a quality assurance program aiming to encourage laboratories to independently determine the quality requirements and evaluate their performance to improve their quality. This program provides data-driven approach to measure quality. The quality measurement is conducted by detecting the medical errors to encourage further improvements. Prodia has been regularly participating in WSVP since 2014.
“Our main focus is to provide a highly qualified, precise, and accurate laboratory test result. We place high importance on the quality of test result so that it will meet the international standards. Prodia’s participation is an effort to consistently maintain the quality of the test result in a sustainable manner,” said Dewi Muliaty, Prodia’s Managing Director, during Westgard QC Seminar at Prodia Tower, Jakarta (13/3).

Further, Sten Westgard, the Director of Client Services and Technology for Westgard QC Inc. USA, stated that Prodia has been consistently implementing the proper quality control (QC) in the examination method, evaluation process, and staff trainings in order to generate the highly accurate medical check-up results. “It is a pride to have Prodia participating in WSVP. Prodia has been proven to provide the high quality services that meet the international standards,” added Sten.

WSVP measures the capability of a laboratory based on its ability to qualify for Six Sigma, the matrix in the analytical quality practice. The value for Six Sigma is calculated based on the value of Allowable Total Error (TEa), bias, and data distribution. Additionally, WSVP also assesses the laboratory’s comprehension on the QC system and procedures. The laboratory will choose at minimum 1 Quality Manager as its representative for WSVP.
WSVP team then assesses and selects the Sigma matrix valuing >4 or more. The assessment will figure out the efforts made by Prodia’s branches to achieve the >4 Sigma value for each parameter provided. For Quality Manager assessment, the success is indicated with the online test result amounting above 70. All Prodia’s branches having passed WSVP achieved Sigma value of >6 on average for Chemistry parameter and >4 for Immunology parameter. Additionally, 11 Quality Managers who attended the assessment process of WSVP have been declared succeed and certified by Westgard team.

Andri Hidayat, Prodia’s Operations and IT Director, confirmed that Prodia’s participation in WSVP is in line with its commitment to provide quality test results, meeting the international standards. “Through WSVP, we proved our consistent effort to maintain the high quality test results useful to support immediate diagnosis by doctors and clinicians,” explained Andri.

Prodia has regularly participated in the national and international quality stabilization and continuously evaluates the results from the External Quality Assessment Scheme (EQAS) for sustainable improvement and consistent quality control system. Prodia has participated in the National Program of External Quality Assurance held by the Ministry of Health and several international quality control programs such as Bio-Rad’s External Quality Assurance Survey (EQAS); Randox’s International Quality Assessment Scheme (RIQAS); quality control from the College of American Pathologists (CAP); Qualiris’ quality control; Cholestest Summit’s quality control; quality control from Royal College of Pathologist of Australasia, Australia (RCPA); and quality control from Medical Laboratory Evaluation (MLE). Prodia acquired satisfactory results in the said programs.

******

About PT Prodia Widyahusada Tbk
 
Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. Mr. Andi Widjaja along with the other founders have been committed to present the best test results with wholehearted services.

As the market leader, since 2012 Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that the quality of the test result from Prodia’s laboratory is equal to those of international laboratories.
 
On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol ‘PRDA’. In that corporate action, Prodia offered 187.5 million shares. Accordingly, the fund raised from the Company’s initial public offering (IPO) was Rp1.22 trillion.

Currently, Prodia has had the service network that incorporates 294 outlets, consisting of 146 clinical laboratories across 34 provinces and 123 cities in Indonesia, Prodia Health Care (PHC) - a personalized medicine-based wellness clinic - and specialty clinics, including Prodia Children’s Health Centre (PCHC), Prodia Women’s Health Centre (PWHC), and Prodia Senior Health Centre (PSHC).     
 
For further information, please contact:
 
Marina Eka Amalia                                                                                           
Legal Head & Corporate Secretary
PT Prodia Widyahusada Tbk                
Ph. +62-21-3144-182 ext. 3816                
E-mail: corporate.secretary@prodia.co.id